ME Therapeutics Holdings Inc.
METX
CNSX
| 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | |
|---|---|---|---|---|---|
| Net Income | -212.10K | -253.90K | -246.70K | -251.40K | -139.70K |
| Total Depreciation and Amortization | 20.70K | 19.00K | 19.40K | 18.30K | 14.30K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.30K | 1.70K | 2.10K | 2.40K | 15.20K |
| Change in Net Operating Assets | -61.40K | 2.00K | 46.50K | 42.60K | -34.60K |
| Cash from Operations | -251.50K | -231.20K | -178.80K | -188.10K | -144.80K |
| Capital Expenditure | -21.70K | -1.20K | -32.50K | -6.20K | -107.60K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 0.00 | -40.90K | 0.00 |
| Cash from Investing | -21.70K | -1.20K | -32.50K | -47.10K | -107.60K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -16.70K | -16.60K | -16.30K | -16.30K | -16.30K |
| Issuance of Common Stock | 0.00 | 184.00K | 0.00 | 0.00 | 1.05M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -12.20K | 119.90K | -11.90K | -11.60K | 722.30K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -285.40K | -112.50K | -223.20K | -246.80K | 469.80K |